-
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists versus other diabetes drugs across 181 outcomes in type 2 diabetes
Against other diabetes drugs, GLP-1 receptor agonists were linked to lower cardiovascular and renal risk but higher musculoskeletal risk.
Peer-reviewed -
Behavioural scienceAdherence and persistence refines
SGLT-2 inhibitors show higher adherence and persistence than GLP-1 RAs in type 2 diabetes
SGLT-2 inhibitors had higher adherence and persistence than GLP-1 receptor agonists in 14,998 matched patients, most clearly with cardiovascular disease.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists cut major cardiovascular events similarly below and above age 65
In eight trials, GLP-1 receptor agonists cut major cardiovascular events similarly above and below 65 (ratio of hazard ratios 1.03).
Peer-reviewed -
Health todayCancer refines
Obesity in Korean adults aged 20 to 39 and risk of early-onset cancer into midlife
Ten-year cancer incidence among young Korean adults was 1.84% at normal weight and 2.62% in class II obesity.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 RA use and neuropsychiatric outcomes in Medicare enrolees with type 2 diabetes
GLP-1 RA users had more depression (HR 1.11) but fewer substance use disorders, dementia and suicidal or self-harm events.
Peer-reviewed -
Behavioural scienceAdherence and persistence confirms
Semaglutide and tirzepatide prescriptions in adults with obesity often end within a year
Of 9,189 adults with obesity but no diabetes starting semaglutide or tirzepatide, 18.6% had coverage for 336 days or more.
Peer-reviewed -
Behavioural scienceDiet, exercise and sleep new
GLP-1/GIP use in US adults rose to 12% by 2025, a third via non-traditional access
GLP-1/GIP use rose from 8.2% to 12.0% of US adults in 18 months, led by weight-loss use.
Preprint · not peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
GLP-1 receptor agonists lower weight and HbA1c in adults taking antipsychotics
In eight trials of antipsychotic-treated adults, GLP-1 receptor agonists lowered weight by 6.54 kg but raised nausea, vomiting and constipation.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Anti-obesity drugs in routine care: short exposure, smaller weight loss than in trials
In routine care, nearly half of tirzepatide users did not reach 10% weight loss after at least 72 weeks.
Peer-reviewed -
Behavioural scienceAdherence and persistence refines
Semaglutide: 14.5% of US initiators start at high dose, with earlier discontinuation
Among US adults starting injectable semaglutide, high-dose initiation was associated with a 25% higher early discontinuation risk and lower 1-year persistence.
Peer-reviewed -
Data, models and systemsWhat linked data reveals new
NHSO-T2DM resource links six Thai routine-care files for 1,421,470 people with diabetes
Six Thai routine-care files were linked by encrypted identifier into registry, visit and drug exposure tables.
Peer-reviewed -
Health todayObesity, diabetes and GLP-1 refines
Type 2 diabetes remission and relapse after metabolic-bariatric procedures in ARMMS-T2D
In ARMMS-T2D, 58% assigned to metabolic-bariatric procedures reached diabetes remission over a median 11 years, against 3% on medical-lifestyle care.
Peer-reviewed